TARGETED ANTI-INFLAMMATORY THERAPEUTICS BIOMARKER-SUPPORTED APPROACHES TO ADDRESS UNMET NEEDS Exalys Therapeutics is developing a portfolio of novel anti-inflammatory therapeutics with best-in-class properties to target a range of diseases with urgent unmet needs and limited treatment options. Exalys is initially targeting postoperative delirium, the most common complication of surgery in olderContinue reading
Investors 2
| Date | Name | Website |
| - | Domain Ass... | domainvc.c... |
| - | Catalys Pa... | catalyspac... |
Mentions in press and media 2
| Date | Title | Description |
| 28.07.2020 | Exalys Therapeutics has raised a $15M Series A to commercialize three potential drug candidates | - |
| 16.07.2020 | Domain Associates and Catalys Pacific Launch Exalys Therapeutics to Develop Portfolio of Next-Generation EP4 Antagonists | The new company is focused on the development of first-in-class therapies for the treatment of inflammatory disorders with an initial target indication of the prevention of postoperative delirium, a serious and potentially life-threatening ... |